CoChat

Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors

Open access
Nukiwa, Mio, Andarini, Sita, Zaini, Jamal, Xin, Hong, Kanehira, Masahiko, Suzuki, Takuji, Fukuhara, Tatsuro, Mizuguchi, Hiroyuki, Hayakawa, Takao, Saijo, Yasuo, Nukiwa, Toshihiro, Kikuchi, Toshiaki · 2006 · European Journal of Immunology
Cited by 45

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Fractalkine (CX3CL1) is a unique membrane‐bound CX3C chemokine that serves as a potent chemoattractant for lymphocytes. The hypothesis of this study is that dendritic cells (DC) genetically modified ex vivo to overexpress fractalkine would enhance the T cell‐mediated cellular immune response with a consequent induction of anti‐tumor immunity to suppress tumor growth. To prove this hypothesis, established tumors of different mouse cancer cells (B16‐F10 melanoma, H‐2 b, and Colon‐26 colon adenocarcinoma, H‐2 d) were treated with intratumoral injection of bone marrow‐derived DC that had been modified in vitro with an RGD fiber‐mutant adenovirus vector expressing mouse fractalkine (Ad‐FKN). In both tumor models tested, treatment of tumor‐bearing mice with Ad‐FKN‐transduced DC gave rise to a significant suppression of tumor growth along with survival advantages in the treated mice. Immunohistochemical analysis of tumors treated with direct injection of Ad‐FKN‐transduced DC demonstrated that the treatment prompted CD8+T cells and CD4+T cells to accumulate in the tumor milieu, leading to activation of immune‐relevant processes. Consistent with the finding, the intratumoral administration of Ad‐FKN‐transduced DC evoked tumor‐specific cytotoxic T lymphocytes, which ensued from in vivo priming of Th1 immune responses in the treated host. In addition, the anti‐tumor effect provided by intratumoral injection of Ad‐FKN‐transduced DC was completely abrogated in CD4+T cell‐deficient mice as well as in CD8+T cell‐deficient mice. These results support the concept that genetic modification of DC with a recombinant fractalkine adenovirus vector may be a useful strategy for cancer immunotherapy protocols.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/eji.200535549

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 45

Metadata

Authors
Nukiwa, M., Andarini, S., Zaini, J., Xin, H., Kanehira, M., Suzuki, T., Fukuhara, T., Mizuguchi, H., Hayakawa, T., Saijo, Y., Nukiwa, T., & Kikuchi, T.
Venue
European Journal of Immunology
Publisher
Wiley
Published
2006-03-29
Volume
36
Issue
4
Pages
1019-1027
ISSN
  • 0014-2980 (ISSN-L)
  • 1521-4141
OpenAlex
W2012203191
Cited by
45
References
2
FWCI
1.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. https://app.cochat.ai/papers/10.1002/eji.200535549
The paper
Nukiwa, M., Andarini, S., Zaini, J., Xin, H., Kanehira, M., Suzuki, T., Fukuhara, T., Mizuguchi, H., Hayakawa, T., Saijo, Y., Nukiwa, T., & Kikuchi, T. (2006). Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors. European Journal of Immunology. https://doi.org/10.1002/eji.200535549

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.